Dapagliflozin (Forxiga)

Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea

Dapagliflozin in Mangement of Pulmonary Hypertension Patients

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions